One of the building blocks for newly launched Clasp Therapeutics Corp. is making the right patient choices for treatment. If those who receive the company’s therapy are correctly identified, CEO Robert Ross told BioWorld, it will have a profound effect on outcomes. The missing link in cancer treatment, Ross added, was how to identify a patient, something he said Clasp is able to do. Read More
Researchers from Foghorn Therapeutics Inc. recently presented preclinical data for FHD-609, a heterobifunctional degrader of BRD9 designed for the treatment of sarcoma. Synthesis and optimization of a series of first-generation compounds led to the identification of FHD-609 as a rapid, selective and highly potent BRD9 degrader, with high plasma stability and acceptable solubility. Read More
Altamira Therapeutics Ltd. has entered into a collaboration agreement with Univercells SA to evaluate the use of the company’s proprietary Semaphore platform for the delivery of mRNA vaccines. Read More
Previous research has shown that adenosine impairs antitumor immunity, and high levels of adenosine and CD73 have been associated with poor prognosis in cancer. Read More
Aptamer Sciences Inc. has filed an IND application with the Korean Ministry of Food and Drug Safety seeking clearance to conduct a phase I trial of AST-201 in patients with GPC3-positive advanced solid tumors. Read More
While there has been progress in the development and availability of treatments and vaccines for Ebola virus (EBOV), there are still no treatments for other filoviruses such as Sudan virus (SUDV, species Sudan ebolavirus), which caused the 2022-23 outbreak in Uganda. Read More
Assembly Biosciences Inc. has disclosed bicyclic heterocycle compounds reported to be useful for the treatment of cytomegalovirus (CMV) and herpes simplex virus (HSV) infections. Read More
China Pharmaceutical University scientists have published details on the discovery and preclinical evaluation of a glutathione peroxidase 4 (GPX4) and cyclin-dependent kinase (CDK) dual inhibitor being developed for the treatment of cancer. Read More
University of Nebraska has described SF-2523 derivatives acting as dual inhibitors of bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) and phosphatidylinositol 3-kinase (PI3K) reported to be useful for the treatment of medulloblastoma and fibrosis. Read More
